¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"glucose effect"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • isotopic effect
    µ¿À§¿ø¼ÒÈ¿°ú
  • inflow effect
    À¯ÀÔÈ¿°ú
  • inotropic effect
    ¼öÃàÃËÁøÈ¿°ú
  • late effect
    ¸¸±âÈ¿°ú
  • latitude effect
    À§µµÈ¿°ú
  • masking effect
    ÀºÆóÈ¿°ú
  • mass effect
    µ¢ÀÌÈ¿°ú, Á¾±«È¿°ú
  • mesomeric effect
    °ø¸íÈ¿°ú
  • magnetic field effect
    ÀÚÀåÈ¿°ú
  • no-observed-effect level
    ¹«°üÂûÈ¿°ú¼öÁØ
  • on-off effect
    °³½ÃÁ¾·áÈ¿°ú
  • osmolality effect
    ¸ô¶ö»ïÅõ¾ÐÈ¿°ú
  • overkill effect
    °úÀ×Ä¡»çÈ¿°ú
  • phase shift effect
    À§»óº¯À§È¿°ú
  • photochemical effect
    ±¤È­ÇÐÈ¿°ú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • dose rate effect
    ¼±·®À²È¿°ú
  • effect
    È¿°ú, ÀÛ¿ë
  • electrophonic effect
    Àü±âû°¢È¿°ú
  • entry slice effect
    ÁøÀÔÀýÆíÈ¿°ú
  • fast scan effect
    °í¼Ó½ºÄµÈ¿°ú
  • gradient echo effect
    ±â¿ï±â¿¡ÄÚÈ¿°ú
  • halo effect
    ´Þ¹«¸®È¿°ú
  • healthy worker effect
    °Ç°­±Ù·ÎÀÚÈ¿°ú
  • in-flow effect
    À¯ÀÔÈ¿°ú
  • indifferent effect
    ¹«°ü½ÉÀÛ¿ë
  • inhibitory effect
    ¾ïÁ¦È¿°ú
  • inotropic effect
    ¼öÃàÃËÁøÈ¿°ú
  • isotopic effect
    µ¿À§¿ø¼ÒÈ¿°ú
  • late effect
    ¸¸±âÈ¿°ú, ÈÄÀ¯È¿°ú
  • latitude effect
    À§µµÈ¿°ú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Bohr effect
    º¸¾Æ È¿°ú(üùÍý)
  • CPE=£¾cytopathogenic effect
    ¼¼Æ÷º´º¯È¿°ú.
  • CPE=£¾cytopathogenic effect
    ¼¼Æ÷º´º¯È¿°ú.
  • Cytopath(ogen)ic effect, CPE
    ¼¼Æ÷º´º¯È¿°ú
  • Donnan effect
    µ·³­È¿°ú
  • Doppler effect
    µµÇ÷¯ È¿°ú
  • Fahraeus-Lindqvist effect
    ÆÄ·¹¿ì½º-¸°Äûºñ½ºÆ® È¿°ú(üùÍý)
  • Fenn effect
    Ææ È¿°ú(üùÍý)
  • Gibbs effect
    ±é½º È¿°ú
  • HIV effect
    HIV È¿°ú<ÀÛ¿ë>
  • Haldane effect
    ÇÒµ§È¿°ú
  • Purkinje effect
    Ǫ¸£Å°´Ï¿¡È¿°ú
  • RF antennae effect
    °íÁÖÆÄ ¾ÈÅ׳ª È¿°ú
  • Stiles-Crawford effect
    ½ºÅ¸ÀϽº-Å©·ÎÆ÷µåÈ¿°ú
  • T1 shortening effect
    T1 ´ÜÃà È¿°ú
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • liquid glucose
    ¾×ü±Û·çÄÚ½º.
  • non-glucose mellituria
    ºñÆ÷µµ´ç´¢¼º ´ç´¢
  • oral glucose tolerance test =OGTT
    °æ±¸Æ÷µµ´çºÎÇϽÃÇè.
  • oxidase-positive glucose fermenter
    »êÈ­È¿¼Ò¾ç¼º Æ÷µµ´ç¹ßÈ¿(Û£ý£)ü
  • random plasma glucose test
    ÀÓÀÇ(Àû)Ç÷Àå´ç½ÃÇè
  • transport maximum of glucose
    Æ÷µµ´ç(øãÔ¬ÓØ)À̵¿ÃÖ°íÄ¡.
  • uridine diphosphate glucose
    ÀÌÀλê¿ì¸®µò±Û·çÄÚ½º.
  • uridine diphosphate glucose-4-epimerase deficiency
    ¿ì¸®µòÀÌÀλê±Û·çÄÚ½º-4-¿¡ÇǸ޶óÁ¦°áÇÌ
  • urinary glucose
    ¿äÆ÷µµ´ç
  • urinary glucose test
    ¿äÆ÷µµ´ç½ÃÇè
  • additive effect
    »ó°¡È¿°ú (ßÓÊ¥üùÍý)
  • additive effect
    ºÎ°¡È¿°ú
  • adverse effect
    ¿ªÈ¿°ú, À¯ÇØÈ¿°ú
  • adverse effect
    ¿ªÈ¿°ú(æ½üùÍý).¾à¸®À¯ÇØÈ¿°ú.
  • air barrier effect
    °ø±â¸·È¿°ú(ÍöѨدüùÍý).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • inductive effect
    À¯µµÈ¿°ú(ë¯ÓôüùÍý)
  • isotope effect
    µ¿À§¿ø¼Ò È¿°ú(ÔÒêÈêªáÈüùÍý)
  • Johnston-Ogston effect
    ÁÔ½ºÅæ-¿À±×½ºÅæ È¿°ú(üùÍý)
  • kerr effect
    Äɸ£ È¿°ú(üùÍý)
  • kinetic isotope effect
    ¹ÝÀÀ¼Óµµ(ÚãëëáÜÓø) µ¿À§¿ø¼ÒÈ¿°ú(ÔÒêÈêªáÈüùÍý)
  • linear electric field effect
    ¼±Çü Àü±âÀåÈ¿°ú(àÊû¡ï³Ñ¨íÞüùÍý)
  • Maxwell effect
    ¸ß½º¿¤ È¿°ú(üùÍý)
  • meiotic effect
    °¨¼öºÐ¿­ È¿°ú(Êõâ¦ÝÂÖ®üùÍý)
  • neighboring group effect
    ±ÙÁ¢±â È¿°ú(ÐÎïÈÐïüùÍý)
  • oligodynamic effect
    ¹Ì·®ÀÛ¿ëÈ¿°ú(Ú°ÕáíÂéÄüùÍý)
  • opsonic effect
    ¿É¼Ò´Ñ È¿°ú(üùÍý)
  • orientation effect
    Á¤À§ È¿°ú(ïÒêÈüùÍý)
  • Pasteur effect
    ÆÄ½ºÅ𸣠ȿ°ú(üùÍý)
  • phospholipid effect
    ÀλêÁöÁúÈ¿°ú(×òß«ò·òõüùÍý)
  • photochemical effect
    ±¤È­ÇÐÈ¿°ú(ÎÃûùùÊüùÍý)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
eff effect; efferent; efficiency; effusion
effect effective
FAE fetal alcohol effect
FET field-effect transistor; forced expiratory time
HWE healthy worker effect; hot water extract
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
NOAEL No Observed Adverse Effect Level
NOEL No Observed Effect Level
NOEC No observed effect concentration
NOE Nuclear Overhauser Effect
NOESY Nuclear Overhauser Effect spectroscopy
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • oral effect of medication
    Åõ¾àÀÇ ±¸°­³» È¿°ú
  • overkill effect
    °úÀ× Ä¡»ç È¿°ú
  • pain-inhibiting effect
    µ¿Åë ¹æÇØ È¿°ú
  • paramagnetic susceptibility effect
    »óÀÚ¼º ÀÚ±âÈ­ È¿°ú
  • period effect
    ±â°£ È¿°ú
  • phase shift effect
    À§»ó º¯À§ È¿°ú
  • photochemical effect
    ±¤È­ÇÐ È¿°ú
    ±âÁú°ú ·¹ÀÌÀú ±¤ÀÇ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ »ý»êµÇ°Å³ª À¯µµµÇ´Â È­ÇÐ ¹ÝÀÀ.
  • physiological effect
    »ý¸®Àû È¿°ú
  • piezo effect
    ÇÇ¿¡Á¶ È¿°ú
  • piezoelectric effect
    ¾ÐÀü È¿°ú
  • pressor effect
    ½Â¾Ð È¿°ú
  • push effect
    ¹Ð¾î³½ È¿°ú
  • radiation effect
    ¹æ»ç¼± È¿°ú
  • radio-frequency thermal effect
    °íÁÖÆÄ ¿­ È¿°ú
  • Raman effect
    ¶ó¸¸ È¿°ú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
phosphoenolpyruvate-glucose phosphotransferase <enzyme> Specific for glucose and nonmetabolizable analogs methyl alpha glucoside, beta-d-thioglucose and 5-thioglucose
Registry number: EC 2.7.1.-
Synonym: II-b(glc) peppts, enzyme II-b(glc) phosphoenolpyruvate phosphotransferase system, enzyme II (glucose), glucose-specific permease, phosphotransferase system, beta-glucosidase permease, beta-glucoside permease, glucose permease, enzyme II(glc), bglp gene product, syta gene product
(26 Jun 1999)
deficiency, glucose-6-phosphate dehydrogenase Deficiency of G6PD is the commonest disease-causing enzyme defect in humans affecting an estimated 400 million people. The G6PD gene is on the X chromosome. Males with the enzyme deficiency develop anaemia due to breakup of their red blood cells when they are exposed to oxidant drugs such as the antimalarial primaquine, the sulfonamide antibiotics or sulfones, naphthalene moth balls, or fava beans.
(12 Dec 1998)
d-glucose D-Glucose;a dextrorotatory monosaccharide (hexose) found in the free state in fruits and other parts of plants, and combined in glucosides, disaccharides (often with fructose in sugars), oligosaccharides, and polysaccharides; it is the product of complete hydrolysis of cellulose, starch, and glycogen. Free glucose also occurs in the blood (normal human concentration, 70 to 110 mg per 100 ml); in diabetes mellitus, it appears in the urine. The epimers of d-glucose are d-allose, d-mannose, d-galactose, and l-idose. Dextrose should not be confused with the l-isomer which is sinistrose.
Synonym: cellohexose.
(05 Mar 2000)
d-glucose 1,6-bisphosphate A bisphosphorylated derivative of d-glucose that is a required intermediate in the interconversion of d-glucose 1-phosphate and d-glucose-6-phosphate.
(05 Mar 2000)
d-glucose 1-phosphate An important intermediate in glycogenesis and glycogenolysis.
Synonym: Cori ester.
(05 Mar 2000)
d-glucose-6-phosphate A key intermediate in glycolysis, glycogenolysis, pentose phosphate shunt, etc.; elevated levels inhibit brain hexokinase and glycolysis.
Synonym: Robison ester, Robison-Embden ester.
(05 Mar 2000)
dolichol phosphate glucose-dolichol diphosphate oligosaccharide glucosyltransferase <enzyme> Can also use dolichol-p-galactose as donor
Registry number: EC 2.4.1.-
Synonym: dolichol-p-glucose-dolichol-p-p-oligosaccharide glucosyltransferase, dolichol-pp-oligosaccharide glucosyltransferase (ii), dolichol-p-p-oligosaccharide glucosyltransferase (i), dol-p-p-oligosaccharide glycosyltransferase, dppo-glucosyltransferase, dolichyl-p-glucose-man(9)(glcnac)2-pp-dolichol glucosyltransferase
(26 Jun 1999)
dTDP-D-glucose synthase <enzyme> Catalyses the formation of dtdp-d-glucose by using glucose-1-phosphate and dttp as substrates; rfba is a dual function enzyme; rfba is also a phosphomannose isomerase-guanosine diphosphomannose pyrophosphorylase; see record of pmi-GMP
Registry number: EC 2.7.7.-
Synonym: rfba protein, deltatdp-glucose synthase, tyla1 gene product, rfba gene product
(26 Jun 1999)
impaired glucose tolerance Blood glucose (sugar) levels higher than normal but not high enough to be called diabetes. People with impaired glucose tolerance may or may not develop diabetes.
Other names (no longer used) for impaired glucose tolerance are borderline, subclinical, chemical, or latent diabetes.
(30 Mar 1998)
test, glucose tolerance After fasting, a specific amount (100 grams) of glucose is given by mouth, and the blood levels of this sugar are measured every hour. Normally, the blood glucose should return to normal within 2 to 2 1/2 hours. The gtt is considered a classic test of carbohydrate metabolism. It is much used in the diagnosis of diabetes. The gtt depends on a number of factors including the ability of the intestine to absorb glucose, the power of the liver to take up and store glucose, the capacity of the pancreas to produce insulin, and the amount of active insulin.
(12 Dec 1998)
UDP-glucose cyanidin-3-rhamnosyl-(1-6)-glucoside-5-O- glucosyltransferase <enzyme> Chemical name: glucosyltransferase, uridine diphosphoglucose-cyanidin 3-rhamnosylglucoside 5-o-
Registry number: EC 2.4.1.-
(26 Jun 1999)
UDP-glucose diosgenin-tigogenin glucosyltransferase <enzyme> Catalyses the glycosylation of steroid saponins; from leaves of eggplant, solanum melongena
Registry number: EC 2.4.1.-
Synonym: udpglc-diosgenin-tigogenin glc-tase, udpglc-dt-glctase, diosgenin glucosyltransferase
(26 Jun 1999)
UDPglucose-glycogen glucose 1-phosphotransferase <enzyme> Catalyses the transfer of glucose 1-phosphate onto c-6 of glucose residues in glycogen to form a phosphodiester
Registry number: EC 2.7.8.-
Synonym: ugg-glcptase
(26 Jun 1999)
UDPglucose-glycoprotein glucose-1-phosphotransferase <enzyme> From embryonic chicken neural retina; glucose is linked by phosphodiester bonds to mannose of a cell surface glycoprotein; catalyses the transfer of alpha glc-1-p from udp-glc to mannose residues on acceptor glycoproteins
Registry number: EC 2.7.8.19
Synonym: glcptase, glc-phosphotransferase
(26 Jun 1999)
UDP-glucose-isoflavone 7-O-glucosyltransferase <enzyme> From c. Arietinum roots; catalyses the 7-o-glucosylation of endogenous isoflavone constituents with udp-glc as glucose donor
Registry number: EC 2.4.1.-
Synonym: udp-gigtransferase
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á